Planning

NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide

  • NHS England

UK2: Preliminary market engagement notice - Procurement Act 2023 - view information about notice types

Notice identifier: 2026/S 000-006070

Procurement identifier (OCID): ocds-h6vhtk-051c39 (view related notices)

Published 23 January 2026, 10:29am



Scope

Reference

CM/PHG/24/5716

Description

NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide

Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Periods of call-offs under the framework agreement:

CM/PHG/24/5716/01– Hospital Only Products - Lenalidomide

CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028

NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028

LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

CM/PHG/24/5716/02 – Hospital Only Products - Pomalidomide

CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028

NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028

LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

CM/PHG/24/5716/03 – Hospital Only Products - Thalidomide

CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028

NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028

LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

Commercial tool

Establishes a framework

Total value (estimated)

  • £196,203,120 excluding VAT
  • £235,443,744 including VAT

Contract dates (estimated)

  • 1 June 2026 to 31 May 2028
  • Possible extension to 31 May 2030
  • 4 years

Main procurement category

Goods

CPV classifications

  • 33600000 - Pharmaceutical products

Engagement

Engagement deadline

30 January 2026

Engagement process description

NHS England is advising suppliers of an upcoming tender for the NHS Generics Pharmaceuticals – Lenalidomide, Pomalidomide & Thalidomide to commence on 1st June 2026 for 24 months with options to extend for a maximum total contract period of 48 months. This procurement will consist Lenalidomide, Pomalidomide and Thalidomide products across all regions of the country. The purpose of this notice is to inform existing and potential new suppliers of this procurement. Useful information for suppliers can be found here www.england.nhs.uk/medicines-2/medicines-value-and-access/medicines-procurement-and-supply-chain/ . Specific information regarding the products included in this procurement will be provided in the ITO which will be issued shortly.


Participation

Particular suitability

Small and medium-sized enterprises (SME)


Submission

Publication date of tender notice (estimated)

2 February 2026


Contracting authority

NHS England

  • Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

United Kingdom

Region: UKI45 - Lambeth

Organisation type: Public authority - central government